Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma

详细信息    查看全文

• 作者：Yun Wang (1)
  Hongxia Li (1)
  Qi Liang (1)
  Bin Liu (2)
  Xiaqi Mei (3)
  Yingji Ma (1)
  
  1. Department of Infectious Disease ; The Fourth Affiliated Hospital of Harbin Medical University ; Yiyuan Street ; Nangang District ; Harbin ; 150001 ; China
  2. Department of Science and Education ; Heilongjiang Province Center for Disease Control and Prevention ; Harbin ; 150036 ; China
  3. Department of Neurology ; The Fourth Affiliated Hospital of Harbin Medical University ; Harbin ; 150001 ; China
  
• 关键词：PD ; 1 ; Sorafenib ; Phosphorylation ; Therapeutic antibody ; Oncogene
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：36
• 期：3
• 页码：1561-1566
• 全文大小：176 KB
• 参考文献：1. Tanaka, S, Arii, S (2012) Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 39: pp. 486-92 CrossRef
  2. Vinas, A (2012) Mapping of DNA sex-specific markers and genes related to sex differentiation in turbot (Scophthalmus maximus). Mar Biotechnol (NY) 14: pp. 655-63 CrossRef
  3. Ng, CK (2012) Deciphering the Sox-Oct partner code by quantitative cooperativity measurements. Nucleic Acids Res 40: pp. 4933-41 CrossRef
  4. Coco, C (2012) Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res 31: pp. 71 CrossRef
  5. Zhang, W (2008) Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 68: pp. 2764-72 CrossRef
  6. Scott, EL, Brann, DW (2013) Estrogen regulation of Dkk1 and Wnt/beta-catenin signaling in neurodegenerative disease. Brain Res 1514: pp. 63-74 CrossRef
  7. Mok, TS (2009) Gefitinib or carboplatin鈥損aclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: pp. 947-57 CrossRef
  8. Mitsudomi, T (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: pp. 121-8 CrossRef
  9. Zhou, C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced PD-L1 mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: pp. 735-42 CrossRef
  10. Failli, V, Bachy, I, R茅taux, S (2002) Expression of the LIM-homeodomain gene Lmx1a (dreher) during development of the mouse nervous system. Mech Dev 118: pp. 225-8 CrossRef
  11. Murray, KD, Choudary, PV, Jones, EG (2007) Nucleus- and cell-specific gene expression in monkey thalamus. Proc Natl Acad Sci 104: pp. 1989-94 CrossRef
  12. Fu, W (2014) Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies. MAbs 6: pp. 978-90 CrossRef
  13. Hu, S (2013) Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor 伪-associated diseases from a molecular view. J Biol Chem 288: pp. 27059-67 CrossRef
  14. Ferlay, J (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: pp. 2893-917 CrossRef
  15. Fujimoto-Ouchi, K (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59: pp. 795-805 CrossRef
  16. Bang, Y-J (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: pp. 687-97 CrossRef
  17. Kute, T (2004) Development of Herceptin resistance in breast cancer cells. Cytometry A 57: pp. 86-93 CrossRef
  18. Lu, Y (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: pp. 1852-7 CrossRef
  19. Nagy, P (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65: pp. 473-82
  20. Price鈥怱chiavi, SA (2002) Rat Muc4 (sialomucin complex) reduces binding of anti鈥怑rbB2 antibodies to tumor cell surfaces, a potential mechanism for Herceptin resistance. Int J Cancer 99: pp. 783-91 CrossRef
  21. Scaltriti, M (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: pp. 628-38 CrossRef
  22. Park, J-G (1990) Characteristics of cell lines established from human gastric carcinoma. Cancer Res 50: pp. 2773-80
  23. Kim, SY (2008) Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 32: pp. 89-95
  24. Cho, H-S (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: pp. 756-60 CrossRef
  25. Knuefermann, C (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: pp. 3205-12 CrossRef
  26. Scagliotti, GV (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: pp. 3543-51 CrossRef
  27. Li, YM (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6: pp. 459-69 CrossRef
  28. Geyer, CE (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: pp. 2733-43 CrossRef
  29. Konecny, GE (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: pp. 1630-9 CrossRef
  30. Schnitt, SJ (2001) Breast cancer in the 21st century: neu opportunities and neu challenges. Mod Pathol 14: pp. 213-8 CrossRef
  31. Bass, AJ (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: pp. 1238-42 CrossRef
  32. Hussenet, T (2010) SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 5: pp. e8960 CrossRef
  33. Yuan, P (2010) Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 5: pp. e9112 CrossRef
  34. Tompkins, DH (2011) Sox2 activates cell proliferation and differentiation in the respiratory epithelium. Am J Respir Cell Mol Biol 45: pp. 101-10 CrossRef
  35. Tompkins, DH (2009) Sox2 is required for maintenance and differentiation of bronchiolar Clara, ciliated, and goblet cells. PLoS One 4: pp. e8248 CrossRef
  36. Aksoy, I (2013) Sox transcription factors require selective interactions with Oct4 and specific transactivation functions to mediate reprogramming. Stem Cells 31: pp. 2632-46 CrossRef
  37. Therasse, P (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: pp. 205-16 CrossRef
  38. Franklin, MC (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: pp. 317-28 CrossRef
  39. Agus, DB (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: pp. 127-37 CrossRef
  40. Muthuswamy, SK, Gilman, M, Brugge, JS (1999) Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 19: pp. 6845-57
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC). Herein, we report that the combinatorial therapy of sorafenib and anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) can be implemented with good results for HCC. Cancer mouse models were used to evaluate therapeutic efficacy and examine the immunologic mechanisms of the sorafenib/anti-PD-L1 mAb therapy. The combined administration of sorafenib and anti-PD-L1 mAb into tumor-bearing mice generated potent immune responses resulting in the complete eradication or remarkable reduction of tumor growth. In some instances, the sorafenib/anti-PD-L1 mAb therapy induced long-lasting protection against tumor rechallenges. The results indicate that NK cells but not CD4T cells or CD8 cells mediated the therapeutic efficacy of this combinatorial therapy. The overall results suggest that immunotherapy consisting of the combination of sorafenib/anti-PD-L1 mAb could be a promising new approach for treating patients with HCC.